Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

PZ0006

Sigma-Aldrich

Exemestan

≥98% (HPLC)

Synonym(e):

6-Methylenandrosta-1,4-dien-3,17-dion

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

5 MG
CHF 121.00
25 MG
CHF 490.00

CHF 121.00

Check Cart for Availability
Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
5 MG
CHF 121.00
25 MG
CHF 490.00

About This Item

Empirische Formel (Hill-System):
C20H24O2
CAS-Nummer:
107868-30-4
Molekulargewicht:
296.40
MDL-Nummer:
MFCD00866994
UNSPSC-Code:
51111800
PubChem Substanz-ID:
329823675
NACRES:
NA.77

CHF 121.00

Check Cart for Availability
Bulk-Bestellung anfordern

Assay

≥98% (HPLC)

Form

powder

Optische Aktivität

[α]/D +250 to +300°, c = 1 in methanol

Farbe

white to off-white

Löslichkeit

DMSO: ≥20 mg/mL

Lagertemp.

2-8°C

SMILES String

C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O

InChI

1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1

InChIKey

BFYIZQONLCFLEV-DAELLWKTSA-N

Angaben zum Gen

human ... CYP19A1(1588)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Biochem./physiol. Wirkung

Exemestane is a steroidal antiestrogen and irreversible aromatase inhibitor. Exemestane acts as a false substrate for the aromatase enzyme. Exemestane also prevents the conversion of androgens to estrogens and is used to treat estrogen-dependent breast cancer.
Exemestane is a steroidal antiestrogen; aromatase inhibitor.

Leistungsmerkmale und Vorteile

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Piktogramme

Health hazardEnvironment
GHS08,GHS09

Signalwort

Danger

H-Sätze

H360,H411

Gefahreneinstufungen

Aquatic Chronic 2 - Repr. 1B

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000362182
0000362182
037M4720V
100M4705

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 7

1 of 7

vibrant-m

Y0001522

Anastrozol

Fulvestrant >98% (HPLC)

Sigma-Aldrich

I4409

Fulvestrant

Fadrozole hydrochloride ≥98% (HPLC)

Sigma-Aldrich

F3806

Fadrozole hydrochloride

Everolimus ≥95% (HPLC)

Sigma-Aldrich

SML2282

Everolimus

Capecitabin ≥98% (HPLC)

Sigma-Aldrich

SML0653

Capecitabin

Letrozol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1540

Letrozol

Raloxifen -hydrochlorid solid

Sigma-Aldrich

R1402

Raloxifen -hydrochlorid

Nan Soon Wong et al.
Expert opinion on pharmacotherapy, 6(13), 2353-2363 (2005-10-13)
Breast cancer is a major health problem in developed countries. Endocrine therapy is a key component in the management of hormone receptor-positive disease. Although tamoxifen has historically been the gold standard in the first-line management of early and advanced breast
Willemien van de Water et al.
The oncologist, 18(1), 8-13 (2012-12-25)
For postmenopausal patients with hormone-sensitive breast cancer, outcome is worse with increasing age at diagnosis. The aim of this study was to assess the incidence of breast cancer recurrence (locoregional and distant), and contralateral breast cancer by age at diagnosis.
Willemien van de Water et al.
European journal of cancer (Oxford, England : 1990), 49(2), 297-304 (2012-09-08)
Multiple studies suggest better efficacy of chemotherapy in invasive ductal breast carcinomas (IDC) than invasive lobular breast carcinomas (ILC). However, data on efficacy of adjuvant endocrine therapy regimens and histological subtypes are sparse. This study assessed endocrine therapy efficacy in
John Fr Robertson et al.
The Lancet. Oncology, 14(3), 228-235 (2013-02-19)
Insulin-like growth factors (IGF-1 and IGF-2) bind to the IGF-1 receptor (IGF-1R), increasing cell proliferation and survival. Ganitumab is a monoclonal IgG1 antibody that blocks IGF-1R. We tested the efficacy and safety of adding ganitumab to endocrine treatment for patients
Anneleen Lintermans et al.
Expert opinion on drug safety, 10(3), 473-487 (2011-03-25)
Hormone-dependent breast cancer can be successfully treated by either blocking the estrogen receptor, as with tamoxifen, or reducing the production of estrogens, as with aromatase inhibitors. Exemestane is a third-generation aromatase inhibitor used in the treatment of estrogen-receptor-positive breast cancer
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.